The radiolabelled product was stable in serum and showed selective and favourable binding to PSMA-positive cells in vitro and in vivo in mice, warranting further evaluation as a clinical agent for imaging PSMA expression in prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.